Digitalis Ventures

Digitalis is a venture capital firm that that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, inventors, and scientists across all stages of venture investing, and our investments span the full continuum of the healthcare ecosystem. It was founded in 2016 and is Headquartered in New York, New York with regional offices in Boston, Los Angeles, and San Francisco.

Cole D.V.M., Ph.D., Cindy

Partner

Auro Nair Ph.D

Partner

Victoria Perweiler

Venture Partner

Misti Ushio

Managing Partner

49 past transactions

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Ness

Seed Round in 2022
Ness builds a credit card-first wedge into healthcare. It allows its user to earn rewards for healthy purchases and access exclusive perks to complement their lifestyle. It was established in 2021 and is based in New York, United States.

Terray Therapeutics

Series A in 2022
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the company addresses complex therapeutic challenges across various targets.

Faeth Therapeutics

Seed Round in 2022
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.

Good Therapeutics

Series B in 2021
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

GRO Biosciences

Series A in 2021
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.

BIOMILQ

Series A in 2021
BIOMILQ is a women-owned and science-led start-up building a mammary biomanufacturing platform to produce bioauthentic human milk ingredients for better human health. By combining the unique capabilities of human mammary cells with a scalable biomanufacturing process, BIOMILQ aims to demonstrate the power of our platform through impact in early-life nutrition with ingredients that promote immune, gut, and neurological development.

Scout Bio

Series B in 2021
Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States.

Kingdom Supercultures

Series A in 2021
Kingdom Supercultures create microbial cultures that help food manufacturers to create new foods with boosted benefits. It re-assembles nature's microbes into new combinations, creating plant-based foods that taste like dairy, low-alcohol beverages with full flavor, and natural preservatives that work as well as artificial ones. They work with clients across diverse industries including food, beverage, personal care, beauty, and more. Their technology comprises an expansive biobank of GRAS microbial strains, high-resolution strain characterization, and new algorithms for predicting and assembling microbial communities.

UnifiHealth

Seed Round in 2021
UnifiHealth is reimagining how health benefits are built and delivered to small businesses. The company was founded in 2019 and based in Columbus, Ohio.

PetMedix

Series B in 2021
PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. they are using the highest quality science to make the therapies their pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, they are applying the cutting edge of science to bring breakthroughs for the animals they love and care for.

Cayaba Care

Seed Round in 2021
Cayaba Care is a maternal health company that provides virtual and in-person wrap-around support throughout the pregnancy and postpartum journey for medium and high risk women. Our multidisciplinary approach is anchored by Maternity Navigators–also certified doulas–who partner with members to ensure successful birth outcomes. We support commercial and Medicaid plans through standard and value-based care contracts to improve quality, experience and achieve significant cost-savings.

Terray Therapeutics

Seed Round in 2021
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the company addresses complex therapeutic challenges across various targets.

AnimalBiome

Venture Round in 2021
AnimalBiome provides personalized nutrition services rooted in the science of the microbiome to improve the gut health of dogs and cats. AnimalBiome’s microbiome tests characterize the gut microbiome of individual pets to help provide useful nutrition recommendations, and its restorative supplements are made with material sourced directly from healthy pets to introduce missing beneficial microbes and balance the microbiome.

Aunt Bertha

Series D in 2021
Aunt Bertha picks up where Uncle Sam leaves off by making it easy to find and apply for government and charitable social service programs. By organizing the world's human service program information, people in need, and the people who help them can find programs in seconds on. They are driving down the cost of administering social service programs by providing a simple way for governments and charities to accept applications online. Aunt Bertha was founded in 2010 and headquartered in Austin, Texas.

Code Ocean

Series A in 2021
Code Ocean is a cloud-based computational reproducibility platform that provides researchers and developers an easy way to share, discover, and run code published in academic journals and conferences. The platform provides open access to the published software code and data to view and download for everyone for free. But the real treat is that users can execute all published code without installing anything on their personal computer. Everything runs in the cloud on CPUs or GPUs according to the user needs.

Ansel Health

Series A in 2021
Ansel Health is a developer of a health insurance platform intended for employers to enhance their employee benefits with a simple supplemental health benefits plan.

Rejuvenate Bio

Series A in 2021
Rejuvenate Bio is a biotechnology company that develops therapies to reverse aging and treat age-related diseases. Founded on research from the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed innovative therapies aimed at addressing chronic age-related diseases in both humans and animals. The company has established a gene therapy pipeline with significant potential in treating chronic diseases. They leverage clinically validated gene targets and an effective delivery method to ensure long-lasting and well-tolerated gene expression.

SeQure Dx

Venture Round in 2021
SeQure Dx provides safety data for on and off-target CRISPR gene editing therapies

UnifiHealth

Seed Round in 2021
UnifiHealth is reimagining how health benefits are built and delivered to small businesses. The company was founded in 2019 and based in Columbus, Ohio.

Onc.AI

Venture Round in 2020
Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment. It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California, United States.

Nuperfect

Seed Round in 2020
Nuperfect is a teeth-straightening company that focuses on invisible teeth correction. The company provides users with personal exclusive correction design solutions and precise customized invisible correction braces. Nuperfect was founded in 2019 and is based in Shenzhen, China.

Ansel Health

Seed Round in 2020
Ansel Health is a developer of a health insurance platform intended for employers to enhance their employee benefits with a simple supplemental health benefits plan.

Smalls

Series A in 2020
Smalls is a direct-to-consumer pet food company that produces human-grade and fresh food for cats. The company's cat food is prepared with human-grade ingredients and offers customized kits as per the cat's nutrition needs, enabling pet owners to get healthy and fresh food directly at their doorstep. It offers variants such as chicken and beef, freeze-dried chicken, and turkey and duck. In 2017, co-founders and best friends Matt Michaelson and Calvin Hughes headquartered the company in New York, New York.

Base5 Genomics

Venture Round in 2020
Base5 Genomics is a developer of sequencing solutions used for personalized care. Its solution reveals the full genomic diversity in humans and other organisms that enable the medical community to give patients the personalized treatment they need. The company was founded in 2018 and is headquartered in Mountain View, California.

Good Therapeutics

Series A in 2020
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Kenzen

Seed Round in 2019
Kenzen’s Mission is to harness the power of physiology data to predict and prevent industrial workforce injuries and improve productivity.

Scratch

Series B in 2019
Scratchpay is a financial technology company that provides payment processing, patient financing, and patient communication tools for veterinary and medical practices. Approximately half of all U.S. veterinary clinics use Scratch's platform to interact and transact with their clients. Scratch's patient financing solution allows patients and pet owners to receive a guaranteed offer in as little as 60 seconds to help them pay for medical care for themselves or a loved one. Scratch's payment processing tools integrate with leading practice management solutions to make checking out a seamless experience for the both the patient and the practice.

The Mighty

Series B in 2019
The Mighty is a digital health community created to empower and connect people facing health challenges and disabilities.

Aunt Bertha

Series C in 2019
Aunt Bertha picks up where Uncle Sam leaves off by making it easy to find and apply for government and charitable social service programs. By organizing the world's human service program information, people in need, and the people who help them can find programs in seconds on. They are driving down the cost of administering social service programs by providing a simple way for governments and charities to accept applications online. Aunt Bertha was founded in 2010 and headquartered in Austin, Texas.

Code Ocean

Series A in 2019
Code Ocean is a cloud-based computational reproducibility platform that provides researchers and developers an easy way to share, discover, and run code published in academic journals and conferences. The platform provides open access to the published software code and data to view and download for everyone for free. But the real treat is that users can execute all published code without installing anything on their personal computer. Everything runs in the cloud on CPUs or GPUs according to the user needs.

Pawp

Seed Round in 2019
Pawp is a digital health clinic and telehealth platform for pet owners and their pets that connects them with veterinary professionals. Pawp gives unlimited 24/7 access to licensed vets and a $3,000/year pet emergency fund. It was founded in 2020 and is headquartered in New York, United States.

Scout Bio

Series B in 2019
Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States.

Terray Therapeutics

Seed Round in 2019
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the company addresses complex therapeutic challenges across various targets.

GRO Biosciences

Seed Round in 2019
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.

PetMedix

Series A in 2019
PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. they are using the highest quality science to make the therapies their pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, they are applying the cutting edge of science to bring breakthroughs for the animals they love and care for.

SchoolCare

Series C in 2019
SchoolCare delivers free health technology for K-12 public schools to help school nurses deliver care and keep students safe. It is a digital health platform for the largest and most consistent health delivery system in the country. Their mission is to work with partners to provide a unified health record for every family. SchoolCare leverages pediatric health data and this country’s most successful public health organization, the K-12 school system, to improve outcomes and learn about clinical health data outside of the provider’s office. Traditional care coordination stops short of sending essential care instructions to School Nurses and thus increases the risk of stopped or inconsistent post-discharge care delivery. By closing the link in the pediatric care continuum, children stay healthy and get better faster.

Good Therapeutics

Series A in 2019
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

MollyBox

Series B in 2018
MollyBox is a subscription-based e-commerce platform for pet-owners. The company offers a monthly themed box of pet foods and supplies. MollyBox was founded in 2015 by Yifu Sun and Yi Ju and is based in Shanghai, China.

Girihlet

Seed Round in 2018
Girihlet is a provider of rapid and accurate deep sequencing services with a unique focus on developing novel technologies. Girihlet currently specializes in inexpensively sequencing and analyzing mtDNA and T cell receptors using novel, bias-free methods in order to harness their power as biomarkers for diagnostics in a variety of disorders.

Rejuvenate Bio

Seed Round in 2018
Rejuvenate Bio is a biotechnology company that develops therapies to reverse aging and treat age-related diseases. Founded on research from the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed innovative therapies aimed at addressing chronic age-related diseases in both humans and animals. The company has established a gene therapy pipeline with significant potential in treating chronic diseases. They leverage clinically validated gene targets and an effective delivery method to ensure long-lasting and well-tolerated gene expression.

Scratch

Series A in 2018
Scratchpay is a financial technology company that provides payment processing, patient financing, and patient communication tools for veterinary and medical practices. Approximately half of all U.S. veterinary clinics use Scratch's platform to interact and transact with their clients. Scratch's patient financing solution allows patients and pet owners to receive a guaranteed offer in as little as 60 seconds to help them pay for medical care for themselves or a loved one. Scratch's payment processing tools integrate with leading practice management solutions to make checking out a seamless experience for the both the patient and the practice.

Kenzen

Convertible Note in 2018
Kenzen’s Mission is to harness the power of physiology data to predict and prevent industrial workforce injuries and improve productivity.

Elemental Machines

Series A in 2018
Elemental Machines is revolutionizing science-based industries with a smart lab platform that offers powerful, data-driven insights to improve laboratory operations, research, development, and manufacturing outcomes. Continuously monitoring equipment and environmental variables provides new levels of clarity, transparency, consistency, and improved repeatability and gathers new data sets for advanced analytics.

GRO Biosciences

Seed Round in 2018
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.

Kenzen

Seed Round in 2017
Kenzen’s Mission is to harness the power of physiology data to predict and prevent industrial workforce injuries and improve productivity.

Somatix

Series A in 2017
Somatix is a software platform developer of wearable-enabled RPM (Remote Patient Monitoring) solutions for healthcare. This cost-effective platform uses patented gesture detection technology, artificial intelligence, and machine learning algorithms to analyze users' gesture data in real-time. The algorithms remotely and passively detect physical and emotional indicators such as risk factors for adverse events, poor medical compliance, inactivity, falls, and dehydration. This data delivers important clinical insights to healthcare providers and organizations helping them maintain continuous contact with and improve the wellbeing of those under their care. The Somatix software platform generates insights using existing sensors embedded in commercial, off-the-shelf smartwatches, smart bands, and IoT devices, as well as Somatix’s own branded smartband.

SchoolCare

Series B in 2016
SchoolCare delivers free health technology for K-12 public schools to help school nurses deliver care and keep students safe. It is a digital health platform for the largest and most consistent health delivery system in the country. Their mission is to work with partners to provide a unified health record for every family. SchoolCare leverages pediatric health data and this country’s most successful public health organization, the K-12 school system, to improve outcomes and learn about clinical health data outside of the provider’s office. Traditional care coordination stops short of sending essential care instructions to School Nurses and thus increases the risk of stopped or inconsistent post-discharge care delivery. By closing the link in the pediatric care continuum, children stay healthy and get better faster.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.